MedTrace Logo

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

NCT00957229 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-01-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.

Conditions

  • Basal Cell Nevus Syndrome
  • Gorlin Syndrome

Interventions

DRUG

GDC-0449

capsule, 150 mg, one pill daily, 18 months

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • UCSF Benioff Children's Hospital Oakland

    lead OTHER

Principal Investigators

  • Ervin Epstein, MD · UCSF Benioff Children's Hospital Oakland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00957229 on ClinicalTrials.gov